2019 Vaccine Guide & Insert - VG11

Additional information

02/22/19

Routine vaccination

*Unvaccinated = Less than routine series (through 14 months)
OR no doses (14 months or older)

y Anatomic or functional asplenia (including sickle cell
disease):
12-59 months
- Unvaccinated or only 1 dose before 12 months: 2 doses,
8 weeks apart
- 2 or more doses before 12 months:1 dose at least 8 weeks
after previous dose
Unvaccinated* persons age 5 years or older
- 1 dose
y Elective splenectomy:
Unvaccinated* persons age 15 months or older
- 1 dose (preferably at least 14 days before procedure)
y HIV infection:
12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses,
8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least
8 weeks after previous dose
Unvaccinated* persons age 5-18 years
- 1 dose
y Immunoglobulin deficiency, early component
complement deficiency:
12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses,
8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least
8 weeks after previous dose

To Fax: 1.800.329.9109 24 Hrs

Centers for Disease Control and Prevention | Recommended Child and Adolescent Immunization Schedule, United States, 2019 | Page 5

y Chemotherapy or radiation treatment:
12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses,
8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least
8 weeks after previous dose
Doses administered within 14 days of starting therapy or during
therapy should be repeated at least 3 months after therapy
completion.
y Hematopoietic stem cell transplant (HSCT):
- 3-dose series 4 weeks apart starting 6 to 12 months after
successful transplant regardless of Hib vaccination history

Special situations

y Dose 1 at 7-11 months: Administer dose 2 at least 4 weeks
later and dose 3 (final dose) at 12-15 months or 8 weeks after
dose 2 (whichever is later).
y Dose 1 at 12-14 months: Administer dose 2 (final dose) at
least 8 weeks after dose 1.
y Dose 1 before 12 months and dose 2 before 15 months:
Administer dose 3 (final dose) 8 weeks after dose 2.
y 2 doses of PedvaxHIB before 12 months: Administer dose 3
(final dose) at 12-59 months and at least 8 weeks after dose 2.
y Unvaccinated at 15-59 months: 1 dose
y For other catch-up guidance, see Table 2.

Catch-up vaccination

y ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 6,
12-15 months
y PedvaxHIB: 3-dose series at 2, 4, 12-15 months

Routine vaccination

Haemophilus influenzae type b vaccination
(minimum age: 6 weeks)

y Dose 5 is not necessary if dose 4 was administered at age
4 years or older.
y For other catch-up guidance, see Table 2.

Catch-up vaccination

y 5-dose series at 2, 4, 6, 15-18 months, 4-6 years
- Prospectively: Dose 4 may be given as early as age
12 months if at least 6 months have elapsed since dose 3.
- Retrospectively: A 4th dose that was inadvertently given as
early as 12 months may be counted if at least 4 months have
elapsed since dose 3.

To Order: 1.800.P.SCHEIN (1.800.772.4346) 8am-8:30pm, et

y The National Vaccine Injury Compensation Program (VICP) is a
no-fault alternative to the traditional legal system for resolving
vaccine injury claims. All routine child and adolescent vaccines
are covered by VICP except for pneumococcal polysaccharide
vaccine (PPSV23). For more information, see www.hrsa.gov/
vaccinecompensation/index.html.

y For information regarding vaccination in the setting of a
vaccine-preventable disease outbreak, contact your state or
local health department.

y For vaccination of persons with immunodeficiencies, see
Table 8-1, Vaccination of persons with primary and secondary
immunodeficiencies, in General Best Practice Guidelines
for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/
general-recs/immunocompetence.html, and Immunization
in Special Clinical Circumstances (In: Kimberlin DW, Brady
MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the
Committee on Infectious Diseases. 31st ed. Itasca, IL: American
Academy of Pediatrics; 2018:67-111).

y Information on travel vaccine requirements and
recommendations is available at wwwnc.cdc.gov/travel/.

y Vaccine doses administered ≤4 days before the minimum
age or interval are considered valid. Doses of any vaccine
administered ≥5 days earlier than the minimum age or
minimum interval should not be counted as valid and should
be repeated as age-appropriate. The repeat dose should be
spaced after the invalid dose by the recommended minimum
interval. For further details, see Table 3-1, Recommended
and minimum ages and intervals between vaccine doses, in
General Best Practice Guidelines for Immunization at www.
cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.

y Within a number range (e.g., 12-18), a dash (-) should be read
as "through."

y For calculating intervals between doses, 4 weeks = 28 days.
Intervals of ≥4 months are determined by calendar months.

y For information on contraindications and precautions for the
use of a vaccine, consult the General Best Practice Guidelines
for Immunization and relevant ACIP statements at www.cdc.
gov/vaccines/hcp/acip-recs/index.html.

y Consult relevant ACIP statements for detailed
recommendations at www.cdc.gov/vaccines/hcp/acip-recs/
index.html.

Diphtheria, tetanus, and pertussis (DTaP)
vaccination (minimum age: 6 weeks [4 years
for Kinrix or Quadracel])

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2019

For vaccine recommendations for persons 19 years of age and
older, see the Recommended Adult Immunization Schedule.

Notes

2019 Vaccine Guide & Insert

Table of Contents for the Digital Edition of 2019 Vaccine Guide & Insert